Toward an observatory of the evolution of clinical trials through phylomemy reconstruction: the COVID-19 vaccines example

J Clin Epidemiol. 2022 Sep:149:36-44. doi: 10.1016/j.jclinepi.2022.05.004. Epub 2022 May 27.

Abstract

Objectives: To visualize the evolution of all registered COVID-19 vaccine trials.

Study design and setting: As part of the living mapping of the COVID-NMA initiative, we identify biweekly all COVID-19 vaccine trials and automatically extract data from the EU clinical trials registry, ClinicalTrials.gov, IRCT and the World Health Organization International Clinical Trials Registry Platform. Data are curated and enriched by epidemiologists. We have used the phylomemy reconstruction process to visualize the temporal evolution of COVID-19 vaccines trials descriptions. We have analyzed the textual contents of 1,794 trials descriptions (last search in October 2021) and explored their collective structure along with their semantic dynamics.

Results: The structures highlighted by the phylomemy reconstruction processes synthesize the complexity of the knowledge produced by the research community. The reconstructed phylomemy clearly retrieves the five major COVID-19 vaccine platforms in the form of complete branches. The branches interactions reflect the exploration of a new approach to vaccine implementation moving from homologous prime vaccination to heterologous prime vaccination. Phylomemies also clearly identifies shifts in research questions, from vaccine efficacy to booster efficacy.

Conclusion: This new method provides important insights for the global coordination between research teams especially in crisis situations such as the COVID-19 pandemic.

Keywords: COVID-19; Knowledge dynamics; Phylomemy; Vaccination; clinical trials; co-word analysis.

MeSH terms

  • COVID-19 Vaccines* / therapeutic use
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Clinical Trials as Topic
  • Humans
  • Pandemics / prevention & control
  • SARS-CoV-2
  • Vaccination / methods

Substances

  • COVID-19 Vaccines